Valuation: Cynata Therapeutics Limited

Market Cap 2.92M 2.06M 1.84M 1.69M 1.53M 2.87M 195M 20.19M 8.11M 103M 7.71M 7.55M 324M P/E 2025
-3.27x
P/E 2026 -0.36x
Enterprise Value 2.02M 1.42M 1.28M 1.17M 1.06M 1.99M 135M 13.99M 5.62M 71.12M 5.34M 5.23M 224M EV / Sales 2025
15.3x
EV / Sales 2026 1.47x
Free-Float
54.57%
Yield 2025 *
-
Yield 2026 -

Last Transcript: Cynata Therapeutics Limited

1 week+9.09%
Current month+9.10%
1 month+9.10%
3 months+0.01%
6 months-96.28%
Current year-96.52%
1 week 0.01
Extreme 0.01
0.01
1 month 0.01
Extreme 0.009999
0.02
Current year 0.01
Extreme 0.009999
0.44
1 year 0.01
Extreme 0.009999
0.44
3 years 0.01
Extreme 0.009999
0.44
5 years 0.01
Extreme 0.009999
0.62
10 years 0.01
Extreme 0.009999
1.87
Manager TitleAgeSince
Corporate Secretary 63 17/05/2012
Director TitleAgeSince
Chairman 65 27/02/2017
Director/Board Member - 30/06/2023
Chairman 70 17/08/2020
Date Insider Type Main position Quantity % Market Cap. Importance
01/06/23 Buy

Chief Executive Officer

55,813 0.0312%
01/06/23 Buy

Chairman

139,534 0.0780%
01/06/23 Buy

Director

139,534 0.0780%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+9.09%-95.64%-90.00% 2.06M
-0.62%+0.50%+33.92%+60.07% 64.38B
+0.35%+3.04%+12.64%+83.62% 56.16B
+0.53%+2.55%+13.90%+104.77% 54.16B
-2.81%-4.31%+23.50%+50.90% 45.33B
-0.33%-1.93%+20.15%+98.45% 42.25B
+0.55%+2.31%+224.97%+942.56% 40.78B
+3.27%+47.96%+112.67%+96.48% 33.8B
+1.22%-1.39%+13.92%+46.95% 32.25B
-1.29%-1.72%+21.00%-6.85% 23.57B
Average +0.08%+5.16%+38.10%+138.69% 39.27B
Weighted average by Cap. +0.01%+3.64%+49.63%+162.36%

Financials

2025 2026
Net sales 1.89M 1.33M 1.19M 1.09M 990K 1.85M 126M 13.03M 5.23M 66.24M 4.98M 4.87M 209M 1.71M 1.2M 1.08M 992K 899K 1.68M 114M 11.83M 4.75M 60.14M 4.52M 4.42M 190M
Net income -9.39M -6.61M -5.92M -5.44M -4.93M -9.22M -627M -64.9M -26.05M -330M -24.79M -24.27M -1.04B -9.25M -6.51M -5.83M -5.36M -4.86M -9.08M -618M -63.92M -25.66M -325M -24.42M -23.9M -1.02B
Net Debt -5.05M -3.55M -3.18M -2.93M -2.65M -4.96M -337M -34.9M -14.01M -177M -13.33M -13.05M -560M -897K -631K -565K -520K -471K -881K -59.95M -6.2M -2.49M -31.53M -2.37M -2.32M -99.45M
Projected Income Statement - Annual - Cynata Therapeutics Limited
Logo Cynata Therapeutics Limited
Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and regenerative medicine company. The Company is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. Cymerus uses induced pluripotent stem cells (iPSCs) to manufacture cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale. Its product candidates include CYP-001, CYP-004 and CYP-006TK. CYP-001 is under Phase II clinical trials with a focus on treatment for steroid-resistant acute graft versus host disease (GvHD) and a Phase 1/II trial in patients undergoing kidney transplantation. CYP-006TK is a Cymerus iPSC-derived MSC topical wound dressing product candidate. This product is used in the Company’s Phase I clinical trial in diabetic foot ulcers (DFU). CYP-004, is an iPSC-derived MSC product for intra-articular injection (injection into a joint), is ongoing with a Phase III trial in patients with osteoarthritis of the knee.
Employees
2
Date Price Change Volume
30/10/26 A$0.0120 0.00% 111,168
29/10/26 A$0.0120 0.00% 83,000
28/10/26 A$0.0120 +9.09% 189,047
27/10/26 A$0.0110 0.00% 300,923
26/10/26 A$0.0110 0.00% 20,000

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Cynata Therapeutics Limited